What is Cerebrolysin?

By Cocer Peptides      1 month ago

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  

The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.

Overview of Cerebrolysin

Cerebrolysin possesses neuroprotective and neurotrophic properties. Since its discovery, it has garnered significant attention in the field of neurological disease treatment. In 1949, Austrian scientist Gerhart Harrer from the University of Innsbruck reported that Cerebrolysin, a protein-based liquid produced through enzymatic hydrolysis of brain tissue, could stimulate nerve cells. It is a protein-based liquid mixture containing 85% free amino acids and 15% bioactive low-molecular-weight amino acid sequences, which include low-molecular-weight neuropeptides such as brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).

Mechanism of Action of Cerebrolysin

Mimicking the Function of Neurotrophic Factors: The active brain neuropeptides in Cerebrolysin can penetrate the blood-brain barrier and mimic the functions of natural neurotrophic factors. Neurotrophic factors are crucial for neuronal survival, growth, differentiation, and synaptic plasticity. Brain-derived neurotrophic factor (BDNF) plays a key role in maintaining normal neuronal function and promoting neural regeneration. The similar components in Cerebrolysin can bind to corresponding receptors on the neuronal surface, activating downstream signaling pathways such as the PI3K-Akt and MAPK signaling pathways, thereby promoting neuronal survival and growth while reducing neuronal apoptosis.

Regulation of the neurotransmitter system: It can exert regulatory effects on the neurotransmitter system. Neurotransmitters play a central role in signal transmission between neurons, and their imbalance is associated with various neurological disorders. Cerebrolysin may maintain the balance of the neurotransmitter system by regulating the release and metabolism of neurotransmitters such as glutamate and gamma-aminobutyric acid (GABA). During cerebral ischemia injury, excessive glutamate release can lead to excitotoxicity, damaging neurons. Cerebrolysin may reduce excitotoxicity-induced neuronal damage by regulating glutamate transporters and decreasing extracellular glutamate accumulation.

Antioxidant stress effects: Neurological diseases are often accompanied by enhanced oxidative stress reactions, where excessive reactive oxygen species (ROS) damage neuronal cell membranes, proteins, and DNA. Cerebrolysin possesses antioxidant stress capabilities, reducing intracellular ROS levels and minimizing oxidative damage. In an in vitro hypoxia-induced neuronal cytotoxicity model, Cerebrolysin can reduce superoxide levels, maintain cellular metabolic activity, and reduce apoptosis. Its specific mechanism may be related to the activation of intracellular antioxidant enzyme systems, such as superoxide dismutase (SOD) and glutathione peroxidase (GPx), which can scavenge ROS and protect neurons from oxidative damage.

Inhibition of inflammatory responses: Inflammatory responses also play a significant role in the development of neurological diseases. Cerebrolysin may alleviate inflammatory responses by inhibiting the release of inflammatory factors and regulating inflammatory signaling pathways. In a cerebral ischemia-reperfusion injury model, Cerebrolysin can reduce the expression of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), while increasing the levels of anti-inflammatory cytokines such as interleukin-10 (IL-10), thereby mitigating inflammatory damage to neurons and promoting the recovery of neural function.

Promoting neural plasticity: Neural plasticity refers to the nervous system's ability to self-repair and reorganize after injury. Cerebrolysin enhances neural plasticity by promoting axonal regeneration, dendritic spine formation, and synaptic reconstruction. It may achieve this by activating relevant signaling pathways, such as the RhoA/ROCK signaling pathway, to regulate changes in the cytoskeleton, thereby promoting axonal growth and extension. Cerebrolysin can also increase the expression of synapse-related proteins, such as synapsin, to promote synapse formation and functional recovery, providing a structural foundation for the restoration of neural function.

The Effects of Cerebrolysin

Effects on acute ischemic stroke: In the treatment of acute ischemic stroke, Cerebrolysin has demonstrated certain positive effects. Although early clinical trials, which primarily enrolled patients with mild strokes, exhibited floor or ceiling effects and failed to clearly demonstrate significant differences between treatment groups, subgroup analyses of patients with more severe strokes revealed its significant positive effects on enhancing recovery. The efficacy of Cerebrolysin increases with the severity of the stroke. Some controlled studies have shown that Cerebrolysin can be safely combined with thrombolytic therapy, and in patients with moderate to severe strokes, it demonstrates efficacy not only in neuroprotection but also in neuro-recovery potential. Compared to neuro-rehabilitation alone, the combination of Cerebrolysin and neuro-rehabilitation yields more significant effects on functional recovery.

Effects on subarachnoid hemorrhage: Subarachnoid hemorrhage (SAH) is an acute neurological condition with high mortality and recovery failure rates. As a drug used for stroke treatment, including SAH, Cerebrolysin's effects on SAH patients have drawn attention. A systematic review and meta-analysis of Cerebrolysin use in SAH patients indicated that the data suggest Cerebrolysin has a positive impact on mortality in SAH patients.

Effects on neonatal hypoxic-ischemic encephalopathy (HIE): HIE is a brain dysfunction caused by perinatal asphyxia, and its pathophysiological mechanisms are not yet fully understood. The current standard treatment is therapeutic hypothermia, but its efficacy is limited. Cerebrolysin, as a neuroprotective treatment, shows potential in the management of HIE. Cerebrolysin has a treatment window of up to six months post-ischemic injury. Administering 0.1 ml/kg body weight of Cerebrolysin twice weekly can improve gross motor and language function deficits in infants, exerting a positive effect on overall outcomes.

Potential role in traumatic brain injury: Traumatic brain injury (TBI) is a common neurological injury that causes neuronal damage and death, leading to a range of neurological dysfunction. Based on Cerebrolysin's neuroprotective and neurotrophic properties, it also holds potential application value in the treatment of TBI. Animal experimental studies have shown that the use of Cerebrolysin can reduce neuronal apoptosis after TBI and promote the recovery of neurological function. Its mechanism of action may be related to multiple mechanisms, including mimicking neurotrophic factor functions, regulating neurotransmitter systems, antioxidant stress, and inhibiting inflammatory responses. Through these mechanisms, it alleviates secondary damage after TBI and promotes neural repair and regeneration.

Potential effects on dementia: Dementia is a neurodegenerative disease characterized by progressive cognitive impairment, with its pathogenesis involving neuronal degeneration and death, neurotransmitter imbalance, inflammatory responses, and oxidative stress. Cerebrolysin's multiple mechanisms of action make it a potential therapeutic agent for dementia. It can promote neuronal survival and growth by mimicking the functions of neurotrophic factors, thereby protecting damaged neurons. By regulating the neurotransmitter system, it improves neurotransmitter imbalance, such as increasing acetylcholine release, thereby enhancing cognitive function. Its antioxidant and anti-inflammatory effects also help reduce neuroinflammation and oxidative damage in the brains of dementia patients, thereby slowing disease progression.

Conclusion

As a drug with neuroprotective and neurotrophic properties, Cerebrolysin has demonstrated therapeutic potential in the treatment of neurological disorders.

References

[1] Kojder K, Jarosz K, Bosiacki M, et al. Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis[J]. Journal of Clinical Medicine, 2023,12. https://api.semanticscholar.org/CorpusID:264397999

[2] Mureșanu D F, Livinț P L, Chira D, et al. Role and Impact of Cerebrolysin for Ischemic Stroke Care[J]. Journal of Clinical Medicine, 2022,11(5).DOI:10.3390/jcm11051273.

[3] Fiani B, Chacon D, Jarrah R, et al. Neuroprotective strategies of cerebrolysin for the treatment of infants with  neonatal hypoxic-ischemic encephalopathy[J]. Acta Neurologica Belgica, 2021,121(6):1401-1406.DOI:10.1007/s13760-021-01795-y.

[4] Al-Mosawi A J. Clinical uses of Cerebrolysin in Pediatric Neuropsychiatry[J]. Science World Journal of Pharmaceutical Sciences, 2020. https://api.semanticscholar.org/CorpusID:235912686

[5] Brainin M. Cerebrolysin: a multi-target drug for recovery after stroke[J]. Expert Review of Neurotherapeutics, 2018,18(8):681-687.DOI:10.1080/14737175.2018.1500459.

[6] Ziganshina L E, Abakumova T. Cerebrolysin for acute ischaemic stroke[J]. Cochrane Database of Systematic Reviews, 2015(6):CD7026.DOI:10.1002/14651858.CD007026.pub3.

[7] Hartwig K, Fackler V, Jaksch-Bogensperger H, et al. Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3β  signaling[J]. International Journal of Developmental Neuroscience, 2014,38:52-58.DOI:10.1016/j.ijdevneu.2014.07.005.

Product available for research use only: